Fgfr1 extracellular domain combination therapies

Abstract

Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

1 . A method of treating lung cancer in a human subject comprising administering to the subject an effective amount of a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) fusion molecule and at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, and topotecan, wherein the FGFR1 ECD fusion molecule comprises an FGFR1 ECD comprising an amino acid sequence selected from SEQ ID NOs: 1 to 4 and a fusion partner. 
     
     
         2 . The method of  claim 1 , wherein the at least one additional therapeutic agent is docetaxel. 
     
     
         3 . The method of  claim 1 , wherein the at least one additional therapeutic agent is paclitaxel. 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein the at least one additional therapeutic agent is vincristine. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the at least one additional therapeutic agent is topotecan. 
     
     
         9 . The method of  claim 1 , wherein the method comprises administering to the subject at least two additional therapeutic agents selected from docetaxel, paclitaxel, vincristine, carboplatin, and topotecan. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 9 , wherein the at least two additional therapeutic agents are paclitaxel and carboplatin. 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the fusion partner is an Fc. 
     
     
         19 . The method of  claim 1 , wherein the FGFR1 ECD fusion molecule comprises a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6. 
     
     
         20 . (canceled) 
     
     
         21 . The method of  claim 1 , wherein the lung cancer is non-small cell lung cancer. 
     
     
         22 . The method of  claim 2 , wherein the fusion partner is an Fc. 
     
     
         23 . The method of  claim 2 , wherein the FGFR1 ECD fusion molecule comprises a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6. 
     
     
         24 . The method of  claim 2 , wherein the cancer is non-small cell lung cancer. 
     
     
         25 . The method of  claim 9 , wherein the fusion partner is an Fc. 
     
     
         26 . The method of  claim 9 , wherein the FGFR1 ECD fusion molecule comprises a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6. 
     
     
         27 . The method of  claim 9 , wherein the lung cancer is non-small cell lung cancer. 
     
     
         28 . The method of  claim 11 , wherein the fusion partner is an Fc. 
     
     
         29 . The method of  claim 11 , wherein the FGFR1 ECD fusion molecule comprises a sequence selected from SEQ ID NO: 5 and SEQ ID NO: 6. 
     
     
         30 . The method of  claim 11 , wherein the lung cancer is non-small cell lung cancer.